The broad-spectrum chemokine inhibitor NR58-3.14.3 suppresses the implantation and survival of human endometrial implants in the nude mice endometriosis model

Basit Öğe Kaydı
dc.authoridBerkkanoglu, Murat/0000-0002-1218-5693
dc.contributor.authorKayisli, Umit A.
dc.contributor.authorBerkkanoglu, Murat
dc.contributor.authorZhang, Lufang
dc.contributor.authorKizilay, Gulnur
dc.contributor.authorArici, Aydin
dc.date.accessioned2024-06-12T11:00:24Z
dc.date.available2024-06-12T11:00:24Z
dc.date.issued2007
dc.departmentTrakya Üniversitesien_US
dc.description.abstractMany chemokines likely contribute to the pathogenesis of endometriosis. The authors hypothesize that the broad-spectrum chemokine inhibitor NR58-3.14.3 may prevent ectopic human endometrium implantation and growth. After placing human endometrium fragments into the peritoneal cavity, ovariectomized athymic nude mice (n = 31) receiving intramuscular estradiol valerate were randomly assigned to daily intraperitoneal injections of either phosphate-buffered saline or NR58-3.14.3. Fourteen days later, the implant number and volume, proliferating cell nuclear antigen (PCNA) and terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labeling (TUNEL) index, and MTT cell viability were assessed in the implants. NR58-3.14.3 reduced the total number (45%) and total volume (81%) of endometriotic lesions (P < .05) and revealed a lower PCNA and higher TUNEL index in ectopic implants compared with controls (P < .05). NR58-3.14.3 treatment did not affect endometrial cell proliferation in vitro. NR58-3.14.3, by possibly regulating cell survival, can reduce the number and size of ectopic implants in vivo, supporting the potential use of chemokine inhibitors in novel therapies for endometriosis.en_US
dc.identifier.doi10.1177/1933719107305865
dc.identifier.endpage835en_US
dc.identifier.issn1933-7205
dc.identifier.issue8en_US
dc.identifier.pmid18089601en_US
dc.identifier.scopus2-s2.0-39049130303en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage825en_US
dc.identifier.urihttps://doi.org/10.1177/1933719107305865
dc.identifier.urihttps://hdl.handle.net/20.500.14551/20813
dc.identifier.volume14en_US
dc.identifier.wosWOS:000252032900013en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofReproductive Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEndometriosisen_US
dc.subjectChemokine Inhibitorsen_US
dc.subjectProliferationen_US
dc.subjectApoptosisen_US
dc.subjectNude Miceen_US
dc.subjectMonocyte Chemotactic Protein-1en_US
dc.subjectEndothelial Growth-Factoren_US
dc.subjectPeritoneal-Fluiden_US
dc.subjectStromal Cellsen_US
dc.subjectInfertile Womenen_US
dc.subjectInterleukin-8en_US
dc.subjectMacrophagesen_US
dc.subjectIdentificationen_US
dc.subjectProliferationen_US
dc.subjectTissueen_US
dc.titleThe broad-spectrum chemokine inhibitor NR58-3.14.3 suppresses the implantation and survival of human endometrial implants in the nude mice endometriosis modelen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu